Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion
Author(s) -
Shelagh B. Coutts,
Véronique Dubuc,
Jennifer Mandzia,
Carol Kenney,
Andrew M. Demchuk,
Eric E. Smith,
Suresh Subramaniam,
Mayank Goyal,
Shivanand Patil,
Bijoy K. Me,
Philip A. Barber,
Dar Dowlatshahi,
Thalia S. Field,
Negar Asdaghi,
Marie-Christine Camden,
Michael D. Hill
Publication year - 2015
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.114.008504
Subject(s) - medicine , modified rankin scale , interquartile range , tenecteplase , stroke (engine) , tissue plasminogen activator , fibrinolytic agent , thrombolysis , population , surgery , myocardial infarction , ischemia , ischemic stroke , mechanical engineering , environmental health , engineering
Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom